Centessa Pharmaceuticals Plc (CNTA) Stock Price & Analysis
Centessa Pharmaceuticals Plc (CNTA) rose 0.15% to USD 39.76 as of June 10, 2026 at 04:59 UTC, according to Nexqual real-time market data.
CNTA last closed at USD 39.7; the session ranged USD 39.58–39.83 on volume of 2,296,040 shares. Market capitalization is $6.15B, with a 52-week range of USD 11.77–40.26 (NMS). Source: Nexqual, June 10, 2026 at 04:59 UTC.
Key Statistics (as of June 10, 2026 at 04:59 UTC)
| Price | USD 39.76 |
|---|---|
| Change | ▲ 0.15% (up) |
| Previous Close | USD 39.7 |
| Open | USD 39.7 |
| Day Range | USD 39.58 – 39.83 |
| 52-Week Range | USD 11.77 – 40.26 |
| Volume | 2,296,040 shares |
| Market Cap | $6.15B |
| Exchange | NMS |
Technical Analysis (CNTA)
Nexqual's technical model rates CNTA "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 04:59 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.83 (neutral) |
| vs SMA50 | Above (USD 39.18) |
| MACD | 0.35 (positive) |
Analyst Ratings (CNTA)
Wall Street analysts rate CNTA "None" based on 7 analysts, with a mean price target of USD 44.57 (range USD 38–62), per Nexqual as of June 10, 2026 at 04:59 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 44.57 |
| High Target | USD 62 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 4 / 9 / 0 |
Earnings (CNTA)
| Next Earnings Date | 2026-05-14 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.52 vs est -0.41 ▼ miss |
| 2025-12-31 | USD -0.48 vs est -0.38 ▼ miss |
| 2025-09-30 | USD -0.41 vs est -0.39 ▼ miss |
| 2025-06-30 | USD -0.38 vs est -0.35 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
Financials & Fundamentals (CNTA)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -57.38% |
| Debt / Equity | 24.33 |
| Current Ratio | 9.53 |
| Total Cash | $276.59M |
| Total Debt | $118.56M |
| Free Cash Flow | $-128.72M |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
Financial Health Score (CNTA)
Nexqual rates Centessa Pharmaceuticals Plc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:59 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $277M cash vs $119M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$129M, burning cash |
| Efficiency | Critical — ROE -57%, ROA -27.4% |
Ownership (CNTA)
| Insider Ownership | +0.51% |
|---|---|
| Institutional Ownership | +96.98% |
| Shares Outstanding | 154.73M |
| Float | 92.48M |
| Short % of Float | +1.96% |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
Leadership (CNTA)
Centessa Pharmaceuticals Plc is led by Mario Alberto Accardi (age 39), CEO & Director, per Nexqual as of June 10, 2026 at 04:59 UTC.
| CEO & Director | Mario Alberto Accardi (age 39) |
|---|---|
| Chief Financial Officer | John J. Crowley (age 51) |
| Chief Technology & Quality Officer | Tia L. Bush (age 54) |
| Senior Vice President of Investor Relations & Corporate Communications | Kristen K. Sheppard Esq. |
| Senior Vice President of Clinical Development Operations | Charlene Stoudt |
Major Backers & Investors (CNTA)
Notable institutional backers of Centessa Pharmaceuticals Plc include Medicxi Ventures Management (Jersey) Ltd, Avoro Capital Advisors LLC, Index Venture Life Associates VI Ltd, according to Nexqual as of June 10, 2026 at 04:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 13.38% |
| Avoro Capital Advisors LLC | 7.66% |
| Index Venture Life Associates VI Ltd | 6.68% |
| Adage Capital Partners GP L.L.C. | 5.98% |
| Pentwater Capital Management Lp | 5.47% |
| FMR, LLC | 4.59% |
| EcoR1 Capital, LLC | 4.02% |
| Perceptive Advisors Llc | 3.52% |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
From Centessa Pharmaceuticals Plc's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
- The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia.
- It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:59 UTC. This page is informational and not investment advice.